arrow
S

Shaun G. Goodman

University of Toronto
H指数:101
被引数:4.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome

脂蛋白(a)、吸烟和糖尿病是急性冠脉综合征后主要不良心血管事件的相加但非交互风险因素

2026-08-310
OAAI
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study

AZALEA-TIMI 71研究中因子XI抑制剂abellacimab的既往抗凝治疗经验与出血风险

Blood
IF23.1
2026-08-011
PRE
Recurrent myocardial infarction identified by centralized troponin review: Insights from the MINT trial

通过集中肌钙蛋白审查识别的复发性心肌梗死:MINT试验的启示

2026-08-010
PRE
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial

限制性或宽松性输血策略患者的输血相关不良事件。MINT试验分析

2025-11-260
OAAI
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Asundexian或Apixaban在根据先前口服抗凝剂使用情况的心房颤动患者中的应用:OCEANIC-AF随机临床试验的亚组分析

2025-06-010
PRE
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia
2025-04-010
OAAI
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism

Factor XI抑制剂用于静脉和动脉血栓栓塞症的预防与治疗

2025-03-310
PRE
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

与脂蛋白(a)、低密度脂蛋白胆固醇及其在Alirocumab作用下变化相关的糖尿病发生风险:ODYSSEY OUTCOMES随机试验的事后分析

2025-02-060
PRE
Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

与利伐沙班相比,FXI抑制剂Abelacimab在抗血小板治疗患者中的出血情况:AZALEA-TIMI 71试验的预先设定分析

2024-11-120
PRE
Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial

基于急性冠脉综合征后及经皮冠状动脉介入治疗后的不同时间点,口服抗凝治疗合并房颤患者中双联与单药抗血小板治疗的相对获益:来自AUGUSTUS试验的启示

2024-11-010
PRE
Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia

四种血红蛋白输血阈值策略对急性心肌梗死合并贫血患者的影响

2024-11-011
PRE
International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial
2024-10-010
PRE